Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTI-1601 in Friedreich's Ataxia
NCT06447025Phase 2Recruiting
- Sponsor
- Larimar Therapeutics
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nomlabofusp in Friedreich's ataxia (FA), sponsored by Larimar Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events up to 24 months, Electrocardiogram parameters up to 24 months and 18 more. Started Jan 2024; status: recruiting.
02
Drugs
nomlabofusp
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT06447025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447025.